LT2780368T - Kompozicijos ir būdai raumenų masės padidinimui ir raumenų sustiprinimui, specifiškai antagonizuojant gdf8 ir (arba) aktiviną a - Google Patents

Kompozicijos ir būdai raumenų masės padidinimui ir raumenų sustiprinimui, specifiškai antagonizuojant gdf8 ir (arba) aktiviną a

Info

Publication number
LT2780368T
LT2780368T LTEP12791657.5T LT12791657T LT2780368T LT 2780368 T LT2780368 T LT 2780368T LT 12791657 T LT12791657 T LT 12791657T LT 2780368 T LT2780368 T LT 2780368T
Authority
LT
Lithuania
Prior art keywords
activin
compositions
methods
muscle
increasing
Prior art date
Application number
LTEP12791657.5T
Other languages
English (en)
Inventor
Trevor Stitt
Esther Latres
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of LT2780368T publication Critical patent/LT2780368T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
LTEP12791657.5T 2011-11-14 2012-11-14 Kompozicijos ir būdai raumenų masės padidinimui ir raumenų sustiprinimui, specifiškai antagonizuojant gdf8 ir (arba) aktiviną a LT2780368T (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161559175P 2011-11-14 2011-11-14
US201261607024P 2012-03-06 2012-03-06
US201261661451P 2012-06-19 2012-06-19
PCT/US2012/064911 WO2013074557A1 (en) 2011-11-14 2012-11-14 Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a

Publications (1)

Publication Number Publication Date
LT2780368T true LT2780368T (lt) 2018-03-12

Family

ID=47228083

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP12791657.5T LT2780368T (lt) 2011-11-14 2012-11-14 Kompozicijos ir būdai raumenų masės padidinimui ir raumenų sustiprinimui, specifiškai antagonizuojant gdf8 ir (arba) aktiviną a

Country Status (19)

Country Link
US (7) US8871209B2 (lt)
EP (1) EP2780368B1 (lt)
JP (1) JP6177249B2 (lt)
KR (1) KR102048189B1 (lt)
AU (1) AU2012339722B2 (lt)
CA (1) CA2855822C (lt)
CY (1) CY1119994T1 (lt)
DK (1) DK2780368T3 (lt)
ES (1) ES2663946T3 (lt)
HK (1) HK1202559A1 (lt)
HR (1) HRP20180201T1 (lt)
HU (1) HUE038570T2 (lt)
LT (1) LT2780368T (lt)
MX (1) MX350355B (lt)
PL (1) PL2780368T3 (lt)
PT (1) PT2780368T (lt)
RS (1) RS56796B1 (lt)
SI (1) SI2780368T1 (lt)
WO (1) WO2013074557A1 (lt)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
EA201390242A1 (ru) 2010-08-16 2013-07-30 Амген Инк. Антитела, связывающие миостатин, композиции и способы
SI2780368T1 (en) * 2011-11-14 2018-04-30 Regeneron Pharmaceuticals, Inc. INGREDIENTS AND PROCEDURES FOR INCREASING PURE MASS AND MICROWAVE WITH SPECIFIC ANTAGONISING OF GDF8 AND / OR ACTIVITY A
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
LT2981822T (lt) 2013-05-06 2020-12-28 Scholar Rock, Inc. Kompozicijos ir būdai, skirti augimo faktoriaus moduliacijai
TW201920262A (zh) * 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
WO2015195094A1 (en) * 2014-06-17 2015-12-23 Ember Therapeutics, Inc. Anti-activin and nati-myostatin antibodies and methods of using the same
US20160075772A1 (en) * 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
EP3215175A4 (en) * 2014-11-06 2018-06-27 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
EA039118B1 (ru) * 2015-04-01 2021-12-07 Ридженерон Фармасьютикалз, Инк. Способ лечения прогрессирующей оссифицирующей фибродисплазии
AU2016249015B2 (en) * 2015-04-15 2022-03-24 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with GDF8 inhibitors
JP6959487B2 (ja) 2015-04-22 2021-11-02 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 筋消耗疾患治療用の新規なハイブリッドａｃｔｒｉｉｂリガンド捕集タンパク質
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
ES2951648T3 (es) 2016-03-11 2023-10-24 Scholar Rock Inc Inmunoglobulinas de unión a Tgfbeta1 y uso de las mismas
CA3031742A1 (en) 2016-08-16 2018-02-22 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
EP3504328A1 (en) 2016-08-24 2019-07-03 Regeneron Pharmaceuticals, Inc. Host cell protein modification
DK3532838T3 (da) 2016-10-25 2022-07-04 Regeneron Pharma Fremgangsmåder og systemer til kromatografidataanalyse
CN110461349A (zh) 2016-11-10 2019-11-15 科乐斯疗法公司 激活素受体iia型变体及其使用方法
CN110382530A (zh) 2017-01-06 2019-10-25 供石公司 亚型特异性、背景许可性TGFβ1抑制剂及其用途
MX2020000228A (es) 2017-07-06 2020-08-10 Regeneron Pharma Proceso de cultivo celular para producir una glicoproteina.
CA3082146A1 (en) 2017-11-09 2019-05-16 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
SG11202004380QA (en) 2017-12-22 2020-06-29 Regeneron Pharma System and method for characterizing drug product impurities
KR20200109330A (ko) 2018-01-12 2020-09-22 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법
JP7349998B2 (ja) 2018-01-31 2023-09-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド サイズバリアントおよび電荷バリアントである薬物製品不純物を特徴解析するためのシステムおよび方法
TWI786265B (zh) 2018-02-02 2022-12-11 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
MX2020008988A (es) 2018-02-28 2020-09-28 Regeneron Pharma Sistemas y metodos para la identificacion de contaminantes virales.
US11248044B2 (en) * 2018-03-01 2022-02-15 Regeneron Pharmaceuticals, Inc. Methods for altering body composition by administering a GDF8 inhibitor and an Activin A inhibitor
KR102503356B1 (ko) 2018-03-19 2023-02-24 리제너론 파마슈티칼스 인코포레이티드 마이크로칩 모세관 전기영동 분석 및 시약
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
TW202005694A (zh) 2018-07-02 2020-02-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
US20210122814A1 (en) 2018-07-11 2021-04-29 Scholar Rock, Inc. HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF
TW202019957A (zh) 2018-07-11 2020-06-01 美商供石公司 TGFβ1抑制劑及其用途
EP3677278B1 (en) 2018-07-11 2021-11-10 Scholar Rock, Inc. Isoform selective tgfbeta1 inhibitors and use thereof
WO2020046793A1 (en) 2018-08-27 2020-03-05 Regeneron Pharmaceuticals, Inc. Use of raman spectroscopy in downstream purification
TW202024639A (zh) 2018-08-30 2020-07-01 美商再生元醫藥公司 用於將蛋白質複合物定特徵之方法
KR20210104744A (ko) * 2018-12-18 2021-08-25 리제너론 파마슈티칼스 인코포레이티드 렙틴 수용체, gdf8 및 액티빈 a에 대한 길항제를 사용하여 체중 및 제지방 근육량을 향상시키기 위한 조성물 및 방법
KR20210114927A (ko) 2019-01-16 2021-09-24 리제너론 파마슈티칼스 인코포레이티드 이황화 결합을 특징 짓는 방법
CA3135004A1 (en) 2019-05-13 2020-11-19 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays
CA3216345A1 (en) 2019-09-24 2021-04-01 Regeneron Pharmaceuticals, Inc. Systems and methods for chromatography use and regeneration
US11730793B2 (en) 2019-11-25 2023-08-22 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous emulsions
AU2021205440A1 (en) 2020-01-11 2022-09-01 Scholar Rock,Inc. TGF-beta inhibitors and use thereof
MX2022008609A (es) 2020-01-11 2022-11-10 Scholar Rock Inc Inhibidores de tgf¿ y uso de los mismos.
US11835527B2 (en) 2020-01-21 2023-12-05 Regeneron Pharmaceuticals, Inc. Deglycosylation methods for electrophoresis of glycosylated proteins
EP4204578A1 (en) 2020-08-31 2023-07-05 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
CN116940347A (zh) 2020-11-25 2023-10-24 里珍纳龙药品有限公司 使用非水性膜乳化的持续释放调配物
MX2023007225A (es) 2020-12-17 2023-06-27 Regeneron Pharma Fabricacion de microgeles encapsuladores de proteina.
WO2022159432A1 (en) 2021-01-20 2022-07-28 Regeneron Pharmaceuticals, Inc. Methods of improving protein titer in cell culture
EP4302098A1 (en) 2021-03-03 2024-01-10 Regeneron Pharmaceuticals, Inc. Systems and methods for quantifying and modifying protein viscosity
JP2024519407A (ja) 2021-03-26 2024-05-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 混合プロトコルを作成するための方法およびシステム
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
AU2022286340A1 (en) 2021-06-01 2024-01-04 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
WO2023039457A1 (en) 2021-09-08 2023-03-16 Regeneron Pharmaceuticals, Inc. A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins
US20230090912A1 (en) 2021-09-20 2023-03-23 Regeneron Pharmaceuticals, Inc. Methods of controlling antibody heterogeneity
AU2022359898A1 (en) 2021-10-07 2024-03-21 Regeneron Pharmaceuticals, Inc. Ph meter calibration and correction
TW202323817A (zh) 2021-10-07 2023-06-16 美商再生元醫藥公司 Ｐｈ建模及控制之系統及方法
WO2023076340A1 (en) 2021-10-26 2023-05-04 Regeneron Pharmaceuticals, Inc. Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
US20230296559A1 (en) 2022-03-18 2023-09-21 Regeneron Pharmaceuticals, Inc. Methods and systems for analyzing polypeptide variants
WO2024064842A1 (en) 2022-09-21 2024-03-28 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
CA2157577C (en) 1993-03-19 2009-11-17 Se-Jin Lee Growth differentiation factor-8
EP1075272B1 (en) 1998-05-06 2009-07-15 Metamorphix, Inc. Methods for treating diabetes by inhibiting gdf-8
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
KR100750695B1 (ko) 1999-07-20 2007-08-22 파멕사 에이/에스 Ｇｄｆ-8 활성을 하향-조절하는 방법
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
WO2004108157A2 (en) 2003-06-02 2004-12-16 Wyeth Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
AU2004312411B8 (en) 2003-12-31 2011-11-24 Schering-Plough Pty. Limited Neutralizing epitope-based growth enhancing vaccine
EP3006039B1 (en) 2004-03-02 2021-01-06 Acceleron Pharma Inc. Alk7 polypeptides for use in promoting fat loss
US20070178095A1 (en) 2004-03-23 2007-08-02 Eli Lilly And Company Anti-myostatin antibodies
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
MX2007000976A (es) 2004-08-12 2007-04-10 Wyeth Corp Tratamiento combinado para diabetes, obesidad y enfermedades cardiovasculares utilizando inhibidores del factor 8 de crecimiento y diferenciacion.
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
DOP2006000093A (es) 2005-04-25 2007-01-31 Pfizer Anticuerpos contra miostatina
BRPI0611069A2 (pt) 2005-05-06 2010-11-09 Zymogenetics Inc anticorpo monoclonal, anticorpo humanizado, fragmento de anticorpo, uso de um antagonista, e, hibridoma
EP1773041A1 (en) 2005-07-21 2007-04-11 Chao-Hung Wu Audio/video data transmission system using the internet to interconnect telephones
JP5415071B2 (ja) 2005-08-19 2014-02-12 ワイス・エルエルシー Ｇｄｆ−８に対するアンタゴニスト抗体ならびにａｌｓおよびその他のｇｄｆ−８関連障害の処置における使用
KR101135220B1 (ko) 2005-10-06 2012-04-24 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체
UA92504C2 (en) * 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
JP2009518422A (ja) 2005-12-06 2009-05-07 アムジェン インコーポレイテッド ミオスタチン・アンタゴニストの使用
US7582298B2 (en) 2006-06-02 2009-09-01 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human IL-6 receptor
AU2007279456A1 (en) 2006-08-03 2008-02-07 Myostin Therapeutics Pty Ltd Myostatin antagonists
RS52787B (en) 2006-09-05 2013-10-31 Eli Lilly And Company MYSTATIN ANTIBODIES
CL2007002567A1 (es) * 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
TWI454479B (zh) 2007-03-06 2014-10-01 Amgen Inc 變異之活動素受體多肽及其用途
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
PT2463282E (pt) 2007-11-05 2013-11-11 Novartis Ag Derivados de 4-benzilamino-1-carboxiacil-piperidina como inibidores de cetp úteis para o tratamento de doenças tais como hiperlipidemia ou arteriosclerose
LT2340031T (lt) 2008-08-14 2019-08-12 Acceleron Pharma Inc. Gdf gaudyklės, skirtos naudoti anemijos gydymui
AR074777A1 (es) 2008-12-19 2011-02-09 Glaxo Group Ltd Proteinas de union a antigeno
CA2749544A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
AU2010243697B2 (en) 2009-04-27 2013-05-23 Novartis Ag Compositions and methods for increasing muscle growth
EP2445936A1 (en) 2009-06-26 2012-05-02 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
ES2658292T3 (es) * 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
AR081556A1 (es) 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
EA201390242A1 (ru) 2010-08-16 2013-07-30 Амген Инк. Антитела, связывающие миостатин, композиции и способы
KR20130132824A (ko) 2010-11-08 2013-12-05 악셀레론 파마 인코포레이티드 Actriia 결합제 및 이의 용도
SI2780368T1 (en) 2011-11-14 2018-04-30 Regeneron Pharmaceuticals, Inc. INGREDIENTS AND PROCEDURES FOR INCREASING PURE MASS AND MICROWAVE WITH SPECIFIC ANTAGONISING OF GDF8 AND / OR ACTIVITY A
GR1007832B (el) 2011-11-21 2013-02-14 Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
SA113340642B1 (ar) 2012-06-15 2015-09-15 فايزر إنك أجسام مضادة معارضة محسنة ضد gdf-8 واستخداماتها
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
EP2951205B1 (en) 2013-02-01 2021-08-11 Santa Maria Biotherapeutics, Inc. Anti-activin-a compounds for the treatment of ovarian cancer
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
EP3033358A2 (en) 2013-08-14 2016-06-22 Novartis AG Methods of treating sporadic inclusion body myositis
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
AU2016249015B2 (en) 2015-04-15 2022-03-24 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with GDF8 inhibitors
US20180008672A1 (en) 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
US11248044B2 (en) 2018-03-01 2022-02-15 Regeneron Pharmaceuticals, Inc. Methods for altering body composition by administering a GDF8 inhibitor and an Activin A inhibitor

Also Published As

Publication number Publication date
US20150010568A1 (en) 2015-01-08
EP2780368A1 (en) 2014-09-24
HRP20180201T1 (hr) 2018-03-09
HK1202559A1 (en) 2015-10-02
AU2012339722A1 (en) 2014-06-05
MX2014005865A (es) 2014-10-17
DK2780368T3 (en) 2018-02-05
AU2012339722B2 (en) 2017-09-14
US20130122007A1 (en) 2013-05-16
KR20140108527A (ko) 2014-09-11
EP2780368B1 (en) 2018-01-03
US20170008956A1 (en) 2017-01-12
WO2013074557A1 (en) 2013-05-23
HUE038570T2 (hu) 2018-10-29
JP2014534239A (ja) 2014-12-18
US11655291B2 (en) 2023-05-23
CA2855822C (en) 2022-11-15
US20170226197A1 (en) 2017-08-10
US10400036B2 (en) 2019-09-03
US8871209B2 (en) 2014-10-28
KR102048189B1 (ko) 2019-11-25
JP6177249B2 (ja) 2017-08-09
MX350355B (es) 2017-09-04
US20240117027A1 (en) 2024-04-11
ES2663946T3 (es) 2018-04-17
SI2780368T1 (en) 2018-04-30
US20200010540A1 (en) 2020-01-09
PT2780368T (pt) 2018-03-22
PL2780368T3 (pl) 2018-06-29
CA2855822A1 (en) 2013-05-23
CY1119994T1 (el) 2018-12-12
RS56796B1 (sr) 2018-04-30
US20180171006A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
HRP20180201T1 (hr) Pripravci i postupci za povećavanje mišićne mase i mišićne čvrstoće specifičnim antagoniziranjem gdf8 i / ili aktivina a
IL251796A0 (en) Methods to suppress muscle atrophy
HK1207299A1 (en) Methods for inhibiting muscle atrophy
IL269489A (en) Compounds, compositions and methods useful for cholesterol mobilization
GB2494937B (en) Mass estimator
EP2731446A4 (en) METHOD AND COMPOSITIONS FOR CONSUMABLE MATERIALS
EP2731451A4 (en) METHODS AND COMPOSITIONS FOR CONSUMABLE PRODUCTS
ZA201306316B (en) Methods and compositions for preparing noribogaine from voacangine
EP3494922C0 (de) Verfahren zur herstellung von teil- oder totalprothesen
EP2552202A4 (en) METHODS AND COMPOSITIONS FOR WEIGHT LOSS
EP2479304A4 (en) PROCESS FOR THE PREPARATION OF ALUMINUM-ZIRCONIUM-TITANIUM-CARBON INTERMEDIATE ALLOY
ZA201403538B (en) Blasting compositions
AP3469A (en) Methods and compositions for inhibiting hiv transmission
EP2738159A4 (en) MERCAPTO-BENZOPHENONE COMPOUNDS, COMPOSITIONS AND METHODS OF PREPARATION THEREOF
EP2702030A4 (en) COMPOSITIONS AND METHODS
EP2766357A4 (en) MESOBILIVERDINE COMPOSITIONS AND METHOD THEREFOR
GB201113315D0 (en) Composition amd method
HK1174328A1 (zh) 用於從伏康京碱製備降伊波加因的方法和組合物
GB201013909D0 (en) A method of balancing a component
GB201013911D0 (en) A method of balancing a component
GB201110658D0 (en) Improved process and compositions